Shots:
- Revvity has received the US FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA), expanding its endocrine diagnostics portfolio
- The portfolio enables direct ChLIA measurement of total testosterone, SHBG, & free testosterone, supporting both first & second-line diagnostic testing for suspected male hypogonadism
- Processed on IDS’ random-access automation platforms, the expanded portfolio enables single-platform testing & offers an alternative to complex ED-LC/MS methods associated with operational & reproducibility challenges
Ref: Businesswire | Image: Revvity | Press Release
Related News: Cepheid Receives IVDR CE Mark for Xpert GI Panel to Detect 11 Gastrointestinal Pathogens
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
